EmergingGrowth.com Reports on Star Scientific, Most Opinions cost More

    EmergingGrowth.com Reports on Star Scientific, Most Opinions cost More

  PR Newswire

  MIAMI, Florida, January 11, 2013

MIAMI, Florida, January 11, 2013 /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, Reports on Star
Scientific. Discussion also includes Phillip Morris, Altria, Reynolds
American, and Lorillard. 

Feature your company on EmergingGrowth.com. Visit EmergingGrowth.com to find
out how. 

Star Scientific (NASDAQ: STSI) has a market cap of $444 million and is
involved in the manufacture, distribution, and sale of consumer products,
dietary supplements, and dissolvable tobacco. The company has a bunch of
mega-cap competitors with Philip Morris (NYSE: PM) (market cap $144bln),
Altria (NYSE: MO) ($65bln), Reynolds American (NYSE: RAI) ($24bln) and
Lorillard (NYSE: LO) ($15.26bln). Star Scientific announced a couple of months
back that it was getting out of the smokeless tobacco business and focusing
instead on hawking dietary supplements. The stock dropped to a 52-week low in
November of $1.56, but has seen a significant rise and is currently trading at
$2.65 (52-week range is $1.56 - $5.05). This coincidentally matches the same
time when institutional funds began completing 13F filings. In the latest
filing, net institutional purchases totaled approximately 13 million shares.
This represents roughly 9.3% of the company's current float of 140 million
shares. On December 14 ^th the stock had a short Interest of 29.5 million,
close to an all-time high and representing about 18% of the 165.8 million
shares outstanding.

The stock has seen a plethora of institutional buying and a fast appreciation
in price from November's low. In the past, much of the company's performance
was based on its success winning lawsuits against the major tobacco companies
for product infringement. Now, there are other catalysts expected to drive the
stock within the next few weeks. In the near future there is going to be a
release of the Johns Hopkins Third Party CRO results testing humans for its
Thyroid treatment using Star Scientific's Anatabloc Technology. Of greatest
importance of course is if the Thyroid results are positive, as this will be
the first time an autoimmune disease has been put into remission. If Star's
Anatabloc Technology can treat or cure one autoimmune disease, in this case
"Hashimoto" Thyroiditis, then there is no reason to think it cannot help cure
other autoimmune diseases such as Diabetes, Rosacea and Alzheimer's.

Clearly this is not just a catalyst but also a ground-breaking event as the
possibilities of the technology are endless and can significantly advance the
medical industry against these aforementioned diseases. The Thyroid research
has been done by the Johns Hopkins University School of Medicine, one of the
most preeminent medical institutions in the world, under the lead of Paul
Ladenson, Hopkins Chief Endocrinologist. It is widely believed that Dr.
Ladenson will use of Anatabloc in Thyroid treatment and that Hopkins will
continue to test this technology, and its efficacy on at least two or three
diseases other than Thyroid.

If the technology is a success, sales of Star's consumer product Anatabloc
will rise significantly and have immediate effects on the company's bottom
line in the upcoming quarters. With any company that is experimenting with new
technology and treatments there is some risk, however, the upside potential is
tremendous considering that the stock trades at $2.65. Most options are more
expensive than picking up some shares of STSI, which has the potential to
revolutionize the industry.

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial
reporters, writers and bloggers in the business, EmergingGrowth.com is
emerging as a leading digital financial media portal. Its services provide
users, subscribers and advertisers with a variety of content and tools through
a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other
financial media companies with its sly approach to reading between the lines
in order to locate that needle in the haystack. Sign up today to see what
EmergingGrowth.com has to offer.

NEW: Feature your company on EmergingGrowth.com. Find out how by filling out
our form at


All information contained herein as well as on the EmergingGrowth.com website
is obtained from sources believed to be reliable but not guaranteed to be
accurate or all-inclusive. All material is for informational purposes only, is
only the opinion of EmergingGrowth.com and should not be construed as an offer
or solicitation to buy or sell securities. In addition, Please make sure you
read and understand the Terms of Use , Privacy Policy and the Disclosure
posted on the EmergingGrowth.com website. Always remember that investing in
securities such as the ones listed within are for high-risk tolerant
individuals only and not the general public. Whether you are an experienced
investor or not, you should always consult with a stockbroker, financial
advisor, or similar before purchasing or selling any securities viewed on any
emails sent from EmergingGrowth.com or its website.

Join our Linked in Group Like us on Facebook

Contact: info@EmergingGrowth.com, +1-305-323-5687
Press spacebar to pause and continue. Press esc to stop.